A pharmacokinetic-pharmacodynamic assessment of the hepatic and bone-marrow toxicities of the new trypanoside fexinidazole

Background of preprint

Fexinidazole, a small molecule containing the nitroimidazole scaffold, has been identified as a potential new treatment for human African trypanosomiasis caused by Trypanosoma brucei gambiense (g-HAT), as well as for Chagas disease. Given the fatality of these diseases and the lack of safe and effective treatments, alternative therapies are urgently needed. First reported by Torreele et al. in 2010 [1], fexinidazole is a promising new treatment given its efficacy against both the blood and central nervous system stages of g-HAT. Unfortunately, progress on taking fexinidazole into the clinic stalled briefly when serological markers measured were suggestive of liver and bone marrow toxicities.

Therefore, Watson et al. had two aims in their study:

• To characterise the relationships between the exposure to fexinidazole and its metabolites, and the potential adverse effects.
• To predict safety of the ten-day fexinidazole regimen developed for g-HAT treatment.

To fulfil the first aim, Watson et al. modelled the formation of the fexinidazole sulfone metabolite M2 as a “first-order absorption” process because fexinidazole is metabolised in vivo to two biologically active metabolites, M1 and M2 (Fig. 1); the latter is a good marker for bioactive exposure for the ten-day treatment of g-HAT using fexinidazole. The authors then made various adjustments to their model in the prediction of this ten-day fexinidazole treatment.

 

Figure 1. Metabolism of fexinidazole to biologically active M1 and M2.

Key findings of preprint

To estimate the exposure to fexinidazole, Watson et al. used a one-compartment disposition model with two transit compartments for M2 formation. The authors also included inter-individual random variability in pharmacokinetic (PK) parameters to improve model fit. Having established the model, Watson et al. then linked liver and bone marrow toxicities to M2 concentrations observed or predicted in the model.

(A) Liver toxicity

Watson et al. analysed data acquired from a previous dose ranging study of fexinidazole used in the treatment of symptomatic Chagas disease patients. The authors used fexinidazole exposure as the predictive variable, and haematological timeseries and liver timeseries as outcome variables. *

From the data summarised in Figure 2 of their paper, the authors made two observations. First, the time-series data exhibited considerable heteroscedasticity. In the context of this paper, this means that the variability of liver transaminase elevation was unequal across the duration of fexinidazole exposure. Second, the authors noted a visible distinction of liver transaminase elevation between patients with high and low M2 exposures, which could be ascribed to total drug exposure.

The authors found that their model revealed a clear relationship between fexinidazole exposure and the outcome of hepatotoxicity, as measured using the both the absolute and relative elevations of liver transaminases. This trend predicted that approximately 50% of individuals with M2 exposures as distributed in the three studies for the g-HAT regimen would experience ALT and AST elevations more than 2.8 times and more than 2 times the baseline respectively; however, no such cases were observed.

(B) Bone marrow toxicity

Using the models constructed on indicators of bone marrow toxicity, Watson et al. found clear exposure-response relationships between M2 exposure and bone marrow toxicity. Specifically, the authors used neutrophil and platelet counts as indicators. In contrast, both the absolute and relative models measuring lymphocytes and haemoglobin levels did not appear to exhibit an exposure-response effect. This led Watson et al. to conclude that the decreases in neutrophil and platelet counts were predictable.

What I like about this preprint

I selected this preprint for its significance in characterising the relationship between fexinidazole’s PK and pharmacodynamic (PD) properties—this preprint focuses on overcoming the current difficulties that must be resolved so that fexinidazole can be used on a wider scale for g-HAT and Chagas disease. Moreover, in highlighting this preprint, I hoped to shed some light on the difficulties associated with predicting the toxicity of a potential drug.

Three such challenges were discussed in this preprint:

• All models run the risk of oversimplification, overfitting, and confounding. This difficulty arises from the maxim that statistical analyses are only as robust as the data that they are built on. In this study, Watson et al. pointed out that the patients suffering from g-HAT were symptomatic, and implied that they may have had higher baseline neutrophil and platelet counts on admission compared to their asymptomatic counterparts in the Chagas study.
• A certain amount of uncertainty may be attributed to the data used in the model. This second point may be associated with the practical limitations of study design. In their model, Watson et al. used M2 AUlogC as an proxy indicator for fexinidazole exposure; this meant that their analysis was limited to drawing associations between M2 exposure and the toxic outcomes experienced by the participants in the trials.
• The applicability of findings generated from experiments and modelling depends heavily on both their statistical and clinical significance. Researchers may sometimes generate statistically significant findings, but these findings must also have pertinent clinical implications in order to be adopted into medical practice. This led Watson et al. to postulate that “the fexinidazole regimen for g-HAT treatment results in mild but predictable delayed reversible decreases in neutrophil and platelet counts”.

Therefore, seen from this perspective, this preprint serves as a useful synthesis in bringing together data from previous clinical studies. In general, clinical studies require tremendous amounts of effort and resources to conduct, which means that they differ greatly in study design depending on the investigators’ resources and constraints. In conducting this research, Watson et al. face the mammoth task of reconciling apparent differences in these clinical studies and clinical trials, assess the prevailing literature, and recommend directions for future research.

Future directions

Based on their findings in this preprint, Watson et al. concluded that the margin of safety for dose-related toxicity is enough to justify the use of fexinidazole in the treatment of g-HAT. Future directions will likely focus on establishing a firmer picture of fexinidazole’s safety profile, which may extend to elucidating its dose-dependent mechanisms of toxicity using in vitro cell-based and in vivo animal-based experiments. At the same time, the potential that fexinidazole exhibits idiosyncratic toxicity must also be considered. Such a possibility may be investigated by assessing clinical symptoms or markers characteristic of immune-mediated reactions to fexinidazole, such as antibody production.

On the other side of the fence, fexinidazole’s PK profile will be further studied. Better assays may be developed that allow researchers to sensitively and specifically measure for concentrations of fexinidazole, M1, and M2. The ability to measure the concentrations of these three moieties in other body fluids such as urine or bile will also serve to propel the understanding of fexnidazole’s PK forward.

Questions for authors

• In Table 2, the OVL of the absolute model for lymphocytes and haemoglobin were 69 and 75 respectively; and the OVL of the relative model for lymphocytes and haemoglobin were 11 and 29 respectively. Similarly, the OVL of the absolute model for platelet EC₅₀ and ALT were 3 and 2 respectively. Previously, in the writeup for Table 2, the OVL appeared to be limited to a range of values between 0 and 1. Therefore, could you elaborate on how the abovementioned OVL values should be interpreted in this context?

References

[1] Torreele E, Bourdin Trunz B, Tweats D, Kaiser M, Brun R, Mazué G, Bray MA, Pécoul B, Fexinidazole – A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness, PLOS Neglected Tropical Diseases 4(12) (2010) e923.

Corrigendum

* This part of the preLight originally read:

Three variables were discussed: (i) liver transaminase levels, a marker of hepatotoxicity; (ii) time series; and (iii) fexinidazole exposure, as estimated using M2 exposures.

The authors have pointed out that this is not exactly correct. Their comments can be read in the author response.

The preLight author is immensely grateful to the preprint authors for their editing suggestions and feedback.

 

Tags: bone marrow toxicity, chagas disease, human african trypanosomiasis, liver toxicity, nitroimidazole

Posted on: 18 December 2018 , updated on: 29 September 2019

doi: https://doi.org/10.1242/prelights.6556

Read preprint (No Ratings Yet)